Penn Davis Mcfarland Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 800 shares of the company’s stock, valued at approximately $404,000.
A number of other institutional investors also recently modified their holdings of the stock. Nordea Investment Management AB lifted its holdings in IDEXX Laboratories by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after buying an additional 1,839 shares during the period. Manning & Napier Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth about $20,418,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after purchasing an additional 1,453 shares in the last quarter. Vanguard Group Inc. grew its position in shares of IDEXX Laboratories by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock valued at $4,576,476,000 after purchasing an additional 98,387 shares during the period. Finally, BNP Paribas acquired a new stake in IDEXX Laboratories during the 1st quarter worth approximately $1,031,000. 87.84% of the stock is owned by institutional investors.
IDEXX Laboratories Trading Down 0.5 %
Shares of NASDAQ:IDXX opened at $457.74 on Monday. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The business has a 50 day moving average of $487.50 and a 200-day moving average of $491.33. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The stock has a market cap of $37.80 billion, a PE ratio of 44.31, a P/E/G ratio of 4.14 and a beta of 1.33.
Wall Street Analysts Forecast Growth
IDXX has been the subject of several research analyst reports. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Finally, StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.
View Our Latest Stock Report on IDXX
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
- Five stocks we like better than IDEXX Laboratories
- How to Calculate Return on Investment (ROI)
- Intuitive Surgical Confirms Bullish Flag: 25% to 30% Upside Ahead
- What Are Dividend Challengers?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is the Nasdaq? Complete Overview with History
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.